-
Mashup Score: 4Rivaroxaban reduces recurrent VTE among patients with obesity - 4 year(s) ago
Rivaroxaban reduced risk for recurrent venous thromboembolism compared with warfarin among patients with VTE and obesity, according to study results presented during International Society on Thrombosis and Haemostasis 2020 Virtual Congress.Results of the study, published simultaneously in Journal of Thrombosis and Thrombolysis, also showed no significant differences in major bleeding with
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The findings demonstrate preliminary stability of FVIII expression at follow-up between 2 and 3.3 years.
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet-
Investigational gene therapy shows stability and durability for hemophilia A. https://t.co/gCNDfMPV77 #ISTH2020 #Haemophilia #Bleedingdisorders #HemoAM https://t.co/kApMiSUhju
-
-
Mashup Score: 0
The findings demonstrate preliminary stability of FVIII expression at follow-up between 2 and 3.3 years.
Source: www.mdedge.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Investigational gene therapy shows stability and durability for hemophilia A. https://t.co/x348RbmtrO #ISTH2020 #Haemophilia #Bleedingdisorders #HemoAM https://t.co/gB6ArSDeqJ
-
-
Mashup Score: 0
The findings demonstrate preliminary stability of FVIII expression at follow-up between 2 and 3.3 years.
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet-
SPK-8011 trial shows efficacy for hemophilia A. https://t.co/6G9DN1iYYR #ISTH2020 #Haemophilia #Bleedingdisorders #HemoAM https://t.co/XJHMCR3SN5
-
-
Mashup Score: 0
The findings demonstrate preliminary stability of FVIII expression at follow-up between 2 and 3.3 years.
Source: www.mdedge.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
SPK-8011 trial shows efficacy for hemophilia A. https://t.co/Iiqab2foGP #ISTH2020 #Haemophilia #Bleedingdisorders #HemoAM https://t.co/XlzcGHmyIm
-
-
Mashup Score: 1ISTH and COVID-19: Abstract Highlights - 4 year(s) ago
Virtual meeting features many presentations on disease’s thrombotic complications
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Here are some research highlights from virtual #ISTH2020 about serious cardiovascular complications that come with #COVID19. By @nicolejlou. https://t.co/h7KfnEO2Uq
-
-
Mashup Score: 0Data Presented From Global and European Analyses of Daiichi Sankyo’s ETNA-VTE Study of Edoxaban - Endovascular Today - 4 year(s) ago
July 15, 2020—Daiichi Sankyo Europe GmbH announced results from five analyses of 12-month data from ETNA-VTE, a noninterventional safety study e
Source: Endovascular TodayCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Data Presented From Global and European Analyses of Daiichi Sankyo’s ETNA-VTE Study of Edoxaban | Presented at #ISTH2020 | @isth https://t.co/wvNHXCyuUp
-
-
Mashup Score: 0Study Evaluates Rivaroxaban Versus Warfarin in Obese Patients With Acute VTE - Endovascular Today - 4 year(s) ago
July 13, 2020—An analysis of electronic health record (EHR) data was conducted to evaluate the effectiveness and safety of rivaroxaban (Xarelto;
Source: Endovascular TodayCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Study Evaluates Rivaroxaban Versus Warfarin in Obese Patients With Acute VTE | Presented at #ISTH2020 | @isth https://t.co/IITuikFwL3
-
-
Mashup Score: 7Thromboinflammation and the hypercoagulability of COVID‐19 - 4 year(s) ago
Click on the article title to read more.
Source: Wiley Online LibraryCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @JTHjournal: Attending #COVID19 session @bhwords #ISTH2020 Want to read more?? @connors_md @JerroldLevy https://t.co/VbDbcKbn9v #open…
-
-
Mashup Score: 23ISTH 2020 Congress: Thrombosis and Hemostasis Conference - 4 year(s) ago
The ISTH 2020 Congress is the leading global event in the field of thrombosis and hemostasis, bringing together thousands of experts to exchange science.
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @isth: If you were unable to attend an #ISTH2020 session, return to https://t.co/GOIBWqMk2d for the recording. Most sessions will be ad…
-
Data presented at #ISTH2020 show that Rivaroxaban (Xarelto, @JanssenGlobal) reduced risk for recurrent venous thromboembolism compared with warfarin among patients with VTE and obesity / Olivia S. Costa (@Olivia_S_Costa) @UConn School of Pharmacy https://t.co/IoUin4lnkK https://t.co/X1aV46qbv8